Drug Details

General Information of the Drug (ID: DR9235)
Name
PD173074
Synonyms
219580-11-7; PD173074; PD 173074; PD-173074; 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; UNII-A4TLL8634Y; A4TLL8634Y; CHEMBL189584; PD-0173074; CHEBI:63448; C28H41N7O3; MFCD08705327; 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 2fgi; N-[2-[[4-(Diethylamino)butyl]amino] -6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-y l]-N'-(1,1-dimethylethyl)urea; SMR000568412; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074; PubChem22593; cc-523; MLS001074892; MLS006011101; SCHEMBL177946; Pyrido[2,3-d]pyrimidine 12; BDBM6190; GTPL5037; AOB2517; DTXSID30176363; EX-A197; SYN1176; BCPP000121; HMS2233G17; HMS3265E09; HMS3265E10; HMS3265F09; HMS3265F10; HMS3371E08; HMS3648A10; HMS3654L09; BCP02368; ZINC3870533; ABP000888; ANW-73236; NSC766908; s1264; AKOS016008595; BCP9001065; CCG-264881; CS-0182; NSC-766908; QC-7737; SB19382; NCGC00165863-01; NCGC00165863-02; NCGC00165863-17; 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea; AC-24850; AK105355; AS-16310; HY-10321; AB0033759; FT-0673540; P2474; SW218104-2; X7486; PD 173074, >=96% (HPLC), powder; A25450; W-5382; PD173074/PD-173074/; SR-01000837541; J-014372; J-523314; SR-01000837541-2; Q27088276; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7; 1-(tert-Butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-yl]urea; 1-tert-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)pyrido(2,3-d)pyrimidin-7-yl)urea; N-(tert-Butyl)-N -[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; N-[2-[[4-(Dethylamno)butyl]amno]-6-(3,5-dmethoxyphenyl)pyrdo[2,3-d ]pyrmdn-7-yl]-n'-(1,1-dmethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1- dimethylethyl)urea; N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; PD 173074;n-[2-[[4-(diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1-dimethylethyl)urea
    Click to Show/Hide
Molecular Type
Small molecule
Disease Nasopharyngeal cancer [ICD-11: 2B6B] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C28H41N7O3
PubChem CID
1401
Canonical SMILES
CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C
InChI
1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)
InChIKey
DXCUKNQANPLTEJ-UHFFFAOYSA-N
CAS Number
CAS 219580-11-7
ChEBI ID
CHEBI:63448
TTD Drug ID
D0VF6E
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Down-regulation Expression c-RAF  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
Down-regulation Expression FGFR1  Molecule Info 
Pathway MAP
Up-regulation Cleavage PARP1  Molecule Info 
Pathway MAP
Down-regulation Expression SRC  Molecule Info 
Pathway MAP
                    In-vitro Model SK-MES-1 CVCL_0630 Lung squamous cell carcinoma Homo sapiens
SW900 CVCL_1731 Lung squamous cell carcinoma Homo sapiens
NCI-H2170 CVCL_1535 Lung squamous cell carcinoma Homo sapiens
                    In-vivo Model The SK-MES-1 xenograft model was developed by subcutaneous injection of 1*107 cells with Matrigel into the upper back of 40 nude mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu).
                    Experimental
                    Result(s)		 Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments.
Target and Pathway
Target(s) Fibroblast growth factor receptor (FGFR)  Molecule Info  [3]
Fusion protein FGFR3-TACC3 (FGFR3-TACC3)  Molecule Info  [1]
Proto-oncogene c-Src (SRC)  Molecule Info  [4]
KEGG Pathway ErbB signaling pathway Click to Show/Hide
2 Rap1 signaling pathway
3 Chemokine signaling pathway
4 Endocytosis
5 VEGF signaling pathway
6 Focal adhesion
7 Adherens junction
8 Tight junction
9 Gap junction
10 Platelet activation
11 GABAergic synapse
12 Inflammatory mediator regulation of TRP channels
13 Regulation of actin cytoskeleton
14 GnRH signaling pathway
15 Estrogen signaling pathway
16 Prolactin signaling pathway
17 Thyroid hormone signaling pathway
18 Oxytocin signaling pathway
19 Bacterial invasion of epithelial cells
20 Epithelial cell signaling in Helicobacter pylori infection
21 Shigellosis
22 Tuberculosis
23 Hepatitis B
24 Viral carcinogenesis
25 Proteoglycans in cancer
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
Panther Pathway Angiogenesis Click to Show/Hide
2 Cadherin signaling pathway
3 Integrin signalling pathway
4 Parkinson disease
5 CCKR signaling map ST
Pathway Interaction Database Endothelins Click to Show/Hide
2 Signaling events mediated by PRL
3 LPA receptor mediated events
4 Atypical NF-kappaB pathway
5 Glypican 1 network
6 Plasma membrane estrogen receptor signaling
7 Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
8 Signaling events mediated by PTP1B
9 S1P3 pathway
10 EPHB forward signaling
11 Nectin adhesion pathway
12 Regulation of p38-alpha and p38-beta
13 CDC42 signaling events
14 Signaling events regulated by Ret tyrosine kinase
15 Arf6 signaling events
16 Signaling events mediated by TCPTP
17 FAS (CD95) signaling pathway
18 Thromboxane A2 receptor signaling
19 Netrin-mediated signaling events
20 Alpha9 beta1 integrin signaling events
21 CXCR4-mediated signaling events
22 EGF receptor (ErbB1) signaling pathway
23 Class I PI3K signaling events
24 Posttranslational regulation of adherens junction stability and dissassembly
25 Regulation of Androgen receptor activity
26 E-cadherin signaling in the nascent adherens junction
27 amb2 Integrin signaling
28 Integrins in angiogenesis
29 ErbB1 downstream signaling
30 Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
31 ErbB2/ErbB3 signaling events
32 EPHA forward signaling
33 E-cadherin signaling in keratinocytes
34 PDGFR-beta signaling pathway
35 Nongenotropic Androgen signaling
36 Internalization of ErbB1
37 CXCR3-mediated signaling events
38 Signaling events mediated by VEGFR1 and VEGFR2
39 Syndecan-2-mediated signaling events
40 Class I PI3K signaling events mediated by Akt
41 Syndecan-3-mediated signaling events
42 Ephrin B reverse signaling
43 Trk receptor signaling mediated by PI3K and PLC-gamma
44 EPHA2 forward signaling
45 Alpha-synuclein signaling
46 FGF signaling pathway
47 Alpha4 beta1 integrin signaling events
48 Signaling events mediated by focal adhesion kinase
WikiPathways ErbB Signaling Pathway Click to Show/Hide
2 Senescence and Autophagy in Cancer
3 Notch Signaling Pathway
4 EPO Receptor Signaling
5 EGF/EGFR Signaling Pathway
6 TGF beta Signaling Pathway
7 Signaling of Hepatocyte Growth Factor Receptor
8 Kit receptor signaling pathway
9 Pregnane X Receptor pathway
10 Aryl Hydrocarbon Receptor Pathway
11 IL-3 Signaling Pathway
12 Nanoparticle-mediated activation of receptor signaling
13 Polycystic Kidney Disease Pathway
14 Alpha 6 Beta 4 signaling pathway
15 BDNF signaling pathway
16 Integrated Pancreatic Cancer Pathway
17 Oncostatin M Signaling Pathway
18 Interleukin-11 Signaling Pathway
19 AGE/RAGE pathway
20 Signaling Pathways in Glioblastoma
21 TSLP Signaling Pathway
22 Arylhydrocarbon receptor (AhR) signaling pathway
23 Regulation of Microtubule Cytoskeleton
24 FSH signaling pathway
25 Leptin signaling pathway
26 RANKL/RANK Signaling Pathway
27 Integrin-mediated Cell Adhesion
28 Angiogenesis
29 Androgen receptor signaling pathway
References
Reference 1 Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21.
Reference 2 Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. Lung Cancer. 2016 Nov;101:111-119.
Reference 3 Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
Reference 4 Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link